Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Earnings Presentation (March 2026)
24 slides from Telix Pharmaceuticals's earnings presentation, Mar 10, 2026
Slide 1: TLX591-Tx ProstACT Global Phase 3 study Part 1 results
Illustration of TLX591-Tx Lutetium (177Lu) rosopatamab tetraxetan Global TLX591-Tx ProstACT Global Phase 3 study (NCT06520345) Part 1 results: Safety and dosimetry March 10, 2026 ASX: TLX | NASDAQ: TLX
Slide 2: Forward looking statements
Forward looking statements This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 3: Presenters
Presenters Guest Speaker Dr. Christian Behrenbruch David N. Cade, MD Pedro C. Barata, MD* Managing Director and Telix Group Chief Medical Oncologist, University Group CEO Medical Officer Hospitals Seidman Cancer Center Associate Professor of Medicine, Case Western Reserve University School of Medici
Slide 4: Introductory remarks
Global Introductory remarks 4
Slide 5: ProstACT Global Phase 3 (Part 1 Lead-in): Key findings
ProstACT Global Phase 3 (Part 1 Lead-in): Key findings Primary and secondary endpoints: Safety and dosimetry Study objectives met: Confirmed safety, pharmacokinetics, dosimetry across cohorts No new safety signals: Hematologic events transient and manageable Tolerability profile supported by dosimet
Slide 6: TLX591-Tx is a novel therapy candidate for prostate cancer
TLX591-Tx is a novel therapy candidate for prostate cancer Differentiated radiopharmaceutical using an antibody (mAb) to target PSMA1 Differentiated radiopharmaceutical using an antibody (mAb) to target PSMA1 TLX591-Tx: Radio antibody-drug conjugate (rADC) approach addresses Lutetium (177Lu) key unm
Slide 7: TLX591-Tx rADC versus 1st generation small molecule RLT
TLX591-Tx rADC versus 1st generation small molecule RLT Key differences underpin PSMA tumor targeting, internalization, and prolonged retention rADC 1st generation RLT5 Radiopharmaceutical TLX591-Tx1-4 Small Molecule description Recommended 2 x 76 mCi 6 x 200 mCi dose (14 days apart) (6 weeks apart)
Slide 8: Study design and patient population
Global Study design and patient population 8
Slide 9: ProstACT Global study design reflects global clinical practice
ProstACT Global study design reflects global clinical practice Allows investigator to combine TLX591-Tx with ARPI or docetaxel Typical clinical practice following disease progression on first ARPI U.S. Predominantly ARPI Switch2 Predominantly Docetaxel3,4,5,6,7,8 • Largest prostate cancer market1 •
Slide 10: ProstACT Global Phase 3 current status
ProstACT Global Phase 3 current status • Enrolling in Australia, New Zealand, & Canada following Part 2 approved in select jurisdictions and enrolling patients IDMC4 review Part 1 complete, prerequisite for progression to Part 2 in U.S.1 • Regulatory approvals obtained allowing study start in China,
Slide 11: Part 1 enrolled 36 patients each with one prior ARPI treatment
Part 1 enrolled 36 patients each with one prior ARPI treatment All patients received two doses of TLX591-Tx Patients screened Key observations for eligibility (n=57) Excluded (n=21) • No treatment-related deaths • Did not meet eligibility • 32 patients remain alive criteria (n=18) • Subject withdrew
Slide 12: Part 1: Baseline demographics and prior treatments
Part 1: Baseline demographics and prior treatments1 Majority of patients (n=36) are 2L mCRPC Baseline age Prior treatments Other prognostic factors demographics Setting of 1st ARPI indication, n (%) PSA4 (ng/dL) at baseline medium range, n mCSPC3 10 (28) Mean 60.3 Slightly older patient population c
Slide 13: Safety
Telix YP Prost ACT ~ Global Safety
Slide 14: Acceptable safety profile confirmed with no new safety signals
Acceptable safety profile confirmed with no new safety signals Non-hematologic events were low grade, hematologic events were transient and manageable ProstACT Global Part 1 (safety TEAE)1 Adverse Grade Grade Grade Grade Total % of Event 1 2 3 4 (n) N=36 Key observations Non-hematologic events Fatig
Slide 15: Hematological profile transient and consistent across cohorts
Hematological profile transient and consistent across cohorts Platelet counts recovered consistently in all three cohorts at ~15 days post nadir TLX591-Tx (2 doses at 76 mCi each) Average platelet counts post-TLX591-Tx (2 doses at 76 mCi each) 1.2 Normalized Platelets (by cohort) 1 0.8 Follow up ong
Slide 16: Dosimetry
()Telix YP ProstACT ~ Global Dosimetry
Slide 17: Pharmacokinetic profile driven by TLX591-Tx residence time
Pharmacokinetic profile driven by TLX591-Tx residence time Demonstrates sustained activity, consistent across cohorts1 Blood radioactivity Lesion activity Key observations Concentrations-Time Profile Concentrations-Time profile • Predictable PK profile: Low inter- patient variability supports reliab
Slide 18: Organ radiation exposure is well below established safety limits
Organ radiation exposure is well below established safety limits Low radiation to salivary glands and kidneys supports tolerability profile Organ mean absorbed dose (Gy) after two cycles of TLX591-Tx (76mCi)1 Key observations • Liver (clearance organ), colon, rectum, spleen, kidney and red marrow me
Slide 19: Lesion dosimetry confirmed TLX591-Tx uptake in tumors
Lesion dosimetry confirmed TLX591-Tx uptake in tumors Meaningful absorbed dose across lesion locations and consistent across cohorts1 Tumor dose (Gy) after the administration of TLX591-Tx in 2 doses of 2812 MBq (76 mCi) 14 days apart Tumor Sites Mean Median Min Max SD All lesions (n=132) 4.83 2.84 0
Slide 20: Patient case: TLX591-Tx plus abiraterone
Patient case: TLX591-Tx plus abiraterone 64-year-old patient with metastatic disease in lymph nodes1 SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days2 * TLX591-Tx seen in the TLX591-Tx seen at vascular space and liver metastatic sites (and liver) Administration of
Slide 21: Patient case: TLX591-Tx sequenced with docetaxel
Patient case: TLX591-Tx sequenced with docetaxel 83-year-old patient with bony metastatic lesions1 SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days2 * TLX591-Tx seen in the TLX591-Tx seen at vascular space and liver metastatic sites (and liver) Administration of on
Slide 22: Summary
()Telix YP ProstACT ~ Global Summary
Slide 23: Summary: ProstACT Global Part 1
Summary: ProstACT Global Part 1 TLX591-Tx plus standard of care has acceptable safety and favorable dosimetry1 • Acceptable and manageable safety and tolerability demonstrated across combination cohorts, no new safety signals or adverse drug- drug interactions • Low radiation exposure to salivary gl
Slide 24: Investor Relations Contacts
Illustration of TLX591-Tx Lutetium (177Lu) rosopatamab tetraxetan Investor Relations Contacts: Kyahn Williamson (Global) SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate
Telix Pharmaceuticals — Earnings Presentation (March 2026) on 6ix